Does treatment change insulin requirements in type 2 diabetes?

The clinician who ordered the panel was not concerned; I would still like to understand it.

The empirical answer seems settled. The explanation does not.

If the honest answer is that nobody knows, I would rather hear that than a plausible story.

What is the causal chain, and where does it stop being established?

To be exact about it, the relevant separation is between glucose lowering, weight reduction and cardiovascular outcome, which are three endpoints from overlapping but distinct trial programmes.

HbA1c reductions of roughly one and a half to two and a quarter percentage points were reported at the higher doses in these programmes, from baselines around eight per cent, with the larger reductions from the higher baselines.

Headline results, principal programmes

Worth being precise here: beta-cell function markers improve during treatment in these trials and revert on withdrawal, which is consistent with functional rather than structural change.

The glucose-dependent mechanism explains most of the safety profile, and it is worth understanding once.

Worth being precise here: the comparator decides how impressive a result looks. Against placebo the class looks excellent; against another modern agent it looks good.

Weight loss contributes to insulin sensitivity independently, so part of the glycaemic effect in a person losing fifteen per cent of body weight is not directly receptor-mediated.

Time-in-range from continuous monitoring is a more informative endpoint than HbA1c for this class specifically, because it captures the postprandial effect that an average conceals.

Cardiovascular outcome trials in the diabetes population — LEADER, SUSTAIN-6, REWIND — established safety and, in those populations, benefit, and they are separate from the glycaemic efficacy programme.

Research-grade material of unverified content cannot support dose reasoning of this kind at all.

Hypoglycaemia risk is about what else is on board, not about this class in isolation.

Hypoglycaemia risk in monotherapy is low in this class because the insulinotropic effect is glucose-dependent, and that is a mechanistic property rather than a trial finding.

The SURPASS programme evaluated tirzepatide in type 2 diabetes across several comparators, and the SUSTAIN programme did the same for semaglutide. Those are the diabetes trials; SURMOUNT and STEP are the obesity ones, and quoting across them is the most common citation error in this area.

Mechanically, gastric emptying delay contributes to postprandial glucose control and attenuates with continued exposure for the short-acting agents, less so for the long-acting ones.

Time-in-range tells you more than a quarterly average for an agent that works postprandially.

Answering this needs the background therapy. Added to metformin alone and added to insulin are different questions with different safety profiles.

Fasting plasma glucose and postprandial excursion respond on different timescales, and a fasting number alone will underestimate what has happened to the postprandial curve.

The glucose-dependence of the insulinotropic effect is established from clamp studies rather than inferred from trial hypoglycaemia rates, which makes it a mechanistic finding rather than a statistical one.

Quote SURPASS and SUSTAIN for glycaemia; quote SURMOUNT and STEP for weight. They are different programmes.

Glucose-dependence is the property that makes the class behave the way it does, and most safety questions here resolve back to it.

Because the insulinotropic effect is glucose-dependent, hypoglycaemia in monotherapy is uncommon. It becomes common when combined with a sulfonylurea or insulin, and that is a dose-adjustment question rather than a class limitation.

Guideline positioning of this class in type 2 diabetes has moved from later-line to earlier over the last several years, on the strength of the outcome rather than the glycaemic data.

Baseline HbA1c drives the size of the reduction more than anything else in the protocol.